The efficacy and safety of everolimus for the treatment of progressive gastroenteropancreatic neuroendocrine tumors: A multi-institution observational study in Taiwan

Chien Ting Liu, Ming Huang Chen, Jen Shi Chen, Li Tzong Chen, Yan-Shen Shan, Chang Hsien Lu, Yu Li Su, Fan Chen Ku, Wen Chi Chou, Yen Yang Chen

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Aim: Everolimus is an inhibitor of mTOR, approved for treatment of advanced pancreatic neuroendocrine tumors (NETs). The purpose of this observational study was to evaluate the efficacy and safety of everolimus in treatment of progressive, advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in Taiwan. Methods: Fifty-three patients with progressive, advanced GEP-NETs who received everolimus treatment between January 2008 and August 2014 were selected. Patient characteristics, tumor features, safety profiles and treatment efficacy were retrospectively analyzed. Results: Mean follow-up duration was 23.7 (1.2–70) months and 37 of 53 patients (69.8%) remained alive at the end of study. The one- and two-year overall survival rates were 90.5% and 75.4%, respectively. The median progression-free survival (PFS) was 18.9 (95% confidence interval; 10.9–26.8) months. Partial response was observed in 15 (28.3%) patients, 29 (54.7%) patients had stable disease and nine (17%) patients had progressive disease. Patients with World Health Organization (WHO) grade I NETs, nonfunctional tumors and liver metastasis burden <10% had significantly better PFS with everolimus treatment. Adverse events observed were stomatitis (35.8%), hyperglycemia (22.6%) and rash (18.8%). Seven (15.4%) patients experienced severe adverse events (grade 3 or more), including hyperglycemia (4.4%), anemia (4.4%), fatigue (2.2%) and elevated liver function (2.2%). One (2.2%) patient died from grade 5 interstitial pneumonitis. Conclusion: Everolimus was an effective treatment for Taiwanese patients with progressive advanced GEP-NETs. Patients with nonfunctional NETs had a trend toward longer PFS, whereas patients with liver metastases burden <10% had a trend toward longer overall survival time receiving everolimus treatment.

Original languageEnglish
Pages (from-to)396-402
Number of pages7
JournalAsia-Pacific Journal of Clinical Oncology
Volume12
Issue number4
DOIs
Publication statusPublished - 2016 Dec 1

Fingerprint

Taiwan
Observational Studies
Safety
Neuroendocrine Tumors
Therapeutics
Disease-Free Survival
Hyperglycemia
Gastro-enteropancreatic neuroendocrine tumor
Everolimus
Liver
Neoplasm Metastasis
Stomatitis
Interstitial Lung Diseases
Exanthema
Fatigue
Anemia
Neoplasms
Survival Rate
Confidence Intervals

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

Liu, Chien Ting ; Chen, Ming Huang ; Chen, Jen Shi ; Chen, Li Tzong ; Shan, Yan-Shen ; Lu, Chang Hsien ; Su, Yu Li ; Ku, Fan Chen ; Chou, Wen Chi ; Chen, Yen Yang. / The efficacy and safety of everolimus for the treatment of progressive gastroenteropancreatic neuroendocrine tumors : A multi-institution observational study in Taiwan. In: Asia-Pacific Journal of Clinical Oncology. 2016 ; Vol. 12, No. 4. pp. 396-402.
@article{6e7c70f76fd94aa2b3e84fcf94d5cd34,
title = "The efficacy and safety of everolimus for the treatment of progressive gastroenteropancreatic neuroendocrine tumors: A multi-institution observational study in Taiwan",
abstract = "Aim: Everolimus is an inhibitor of mTOR, approved for treatment of advanced pancreatic neuroendocrine tumors (NETs). The purpose of this observational study was to evaluate the efficacy and safety of everolimus in treatment of progressive, advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in Taiwan. Methods: Fifty-three patients with progressive, advanced GEP-NETs who received everolimus treatment between January 2008 and August 2014 were selected. Patient characteristics, tumor features, safety profiles and treatment efficacy were retrospectively analyzed. Results: Mean follow-up duration was 23.7 (1.2–70) months and 37 of 53 patients (69.8{\%}) remained alive at the end of study. The one- and two-year overall survival rates were 90.5{\%} and 75.4{\%}, respectively. The median progression-free survival (PFS) was 18.9 (95{\%} confidence interval; 10.9–26.8) months. Partial response was observed in 15 (28.3{\%}) patients, 29 (54.7{\%}) patients had stable disease and nine (17{\%}) patients had progressive disease. Patients with World Health Organization (WHO) grade I NETs, nonfunctional tumors and liver metastasis burden <10{\%} had significantly better PFS with everolimus treatment. Adverse events observed were stomatitis (35.8{\%}), hyperglycemia (22.6{\%}) and rash (18.8{\%}). Seven (15.4{\%}) patients experienced severe adverse events (grade 3 or more), including hyperglycemia (4.4{\%}), anemia (4.4{\%}), fatigue (2.2{\%}) and elevated liver function (2.2{\%}). One (2.2{\%}) patient died from grade 5 interstitial pneumonitis. Conclusion: Everolimus was an effective treatment for Taiwanese patients with progressive advanced GEP-NETs. Patients with nonfunctional NETs had a trend toward longer PFS, whereas patients with liver metastases burden <10{\%} had a trend toward longer overall survival time receiving everolimus treatment.",
author = "Liu, {Chien Ting} and Chen, {Ming Huang} and Chen, {Jen Shi} and Chen, {Li Tzong} and Yan-Shen Shan and Lu, {Chang Hsien} and Su, {Yu Li} and Ku, {Fan Chen} and Chou, {Wen Chi} and Chen, {Yen Yang}",
year = "2016",
month = "12",
day = "1",
doi = "10.1111/ajco.12571",
language = "English",
volume = "12",
pages = "396--402",
journal = "Asia-Pacific Journal of Clinical Oncology",
issn = "1743-7555",
publisher = "Wiley-Blackwell",
number = "4",

}

The efficacy and safety of everolimus for the treatment of progressive gastroenteropancreatic neuroendocrine tumors : A multi-institution observational study in Taiwan. / Liu, Chien Ting; Chen, Ming Huang; Chen, Jen Shi; Chen, Li Tzong; Shan, Yan-Shen; Lu, Chang Hsien; Su, Yu Li; Ku, Fan Chen; Chou, Wen Chi; Chen, Yen Yang.

In: Asia-Pacific Journal of Clinical Oncology, Vol. 12, No. 4, 01.12.2016, p. 396-402.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The efficacy and safety of everolimus for the treatment of progressive gastroenteropancreatic neuroendocrine tumors

T2 - A multi-institution observational study in Taiwan

AU - Liu, Chien Ting

AU - Chen, Ming Huang

AU - Chen, Jen Shi

AU - Chen, Li Tzong

AU - Shan, Yan-Shen

AU - Lu, Chang Hsien

AU - Su, Yu Li

AU - Ku, Fan Chen

AU - Chou, Wen Chi

AU - Chen, Yen Yang

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Aim: Everolimus is an inhibitor of mTOR, approved for treatment of advanced pancreatic neuroendocrine tumors (NETs). The purpose of this observational study was to evaluate the efficacy and safety of everolimus in treatment of progressive, advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in Taiwan. Methods: Fifty-three patients with progressive, advanced GEP-NETs who received everolimus treatment between January 2008 and August 2014 were selected. Patient characteristics, tumor features, safety profiles and treatment efficacy were retrospectively analyzed. Results: Mean follow-up duration was 23.7 (1.2–70) months and 37 of 53 patients (69.8%) remained alive at the end of study. The one- and two-year overall survival rates were 90.5% and 75.4%, respectively. The median progression-free survival (PFS) was 18.9 (95% confidence interval; 10.9–26.8) months. Partial response was observed in 15 (28.3%) patients, 29 (54.7%) patients had stable disease and nine (17%) patients had progressive disease. Patients with World Health Organization (WHO) grade I NETs, nonfunctional tumors and liver metastasis burden <10% had significantly better PFS with everolimus treatment. Adverse events observed were stomatitis (35.8%), hyperglycemia (22.6%) and rash (18.8%). Seven (15.4%) patients experienced severe adverse events (grade 3 or more), including hyperglycemia (4.4%), anemia (4.4%), fatigue (2.2%) and elevated liver function (2.2%). One (2.2%) patient died from grade 5 interstitial pneumonitis. Conclusion: Everolimus was an effective treatment for Taiwanese patients with progressive advanced GEP-NETs. Patients with nonfunctional NETs had a trend toward longer PFS, whereas patients with liver metastases burden <10% had a trend toward longer overall survival time receiving everolimus treatment.

AB - Aim: Everolimus is an inhibitor of mTOR, approved for treatment of advanced pancreatic neuroendocrine tumors (NETs). The purpose of this observational study was to evaluate the efficacy and safety of everolimus in treatment of progressive, advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in Taiwan. Methods: Fifty-three patients with progressive, advanced GEP-NETs who received everolimus treatment between January 2008 and August 2014 were selected. Patient characteristics, tumor features, safety profiles and treatment efficacy were retrospectively analyzed. Results: Mean follow-up duration was 23.7 (1.2–70) months and 37 of 53 patients (69.8%) remained alive at the end of study. The one- and two-year overall survival rates were 90.5% and 75.4%, respectively. The median progression-free survival (PFS) was 18.9 (95% confidence interval; 10.9–26.8) months. Partial response was observed in 15 (28.3%) patients, 29 (54.7%) patients had stable disease and nine (17%) patients had progressive disease. Patients with World Health Organization (WHO) grade I NETs, nonfunctional tumors and liver metastasis burden <10% had significantly better PFS with everolimus treatment. Adverse events observed were stomatitis (35.8%), hyperglycemia (22.6%) and rash (18.8%). Seven (15.4%) patients experienced severe adverse events (grade 3 or more), including hyperglycemia (4.4%), anemia (4.4%), fatigue (2.2%) and elevated liver function (2.2%). One (2.2%) patient died from grade 5 interstitial pneumonitis. Conclusion: Everolimus was an effective treatment for Taiwanese patients with progressive advanced GEP-NETs. Patients with nonfunctional NETs had a trend toward longer PFS, whereas patients with liver metastases burden <10% had a trend toward longer overall survival time receiving everolimus treatment.

UR - http://www.scopus.com/inward/record.url?scp=84994164436&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994164436&partnerID=8YFLogxK

U2 - 10.1111/ajco.12571

DO - 10.1111/ajco.12571

M3 - Article

C2 - 27357443

AN - SCOPUS:84994164436

VL - 12

SP - 396

EP - 402

JO - Asia-Pacific Journal of Clinical Oncology

JF - Asia-Pacific Journal of Clinical Oncology

SN - 1743-7555

IS - 4

ER -